FDAsafety guidance83% confidence
Guidance Documents for Rare Disease Drug Development
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Eli Lilly.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Infectious Disease · Viral and Bacterial Pathogens
- Sub-indication
- General
Related signal: Lilly expands infectious disease portfolio with three strategic acquisitions